RBx 9001

Drug Profile

RBx 9001

Latest Information Update: 06 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ranbaxy Laboratories
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
  • 02 May 2004 Phase-I clinical trials in Benign prostatic hyperplasia in India (unspecified route)
  • 02 May 2004 Ranbaxy has received approval from the Drugs Controller General of India to begin phase I trials with RBx 9001
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top